Abstract
Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.
| Original language | English |
|---|---|
| Pages (from-to) | 297-301 |
| Number of pages | 5 |
| Journal | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi |
| Volume | 46 |
| Issue number | 4 |
| Publication status | Published - 2005 Jan 1 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy. / Park, Sang Hoon; Jeen, Yoon Tae; Chun, Hwang Rae; Kim, Dong Il; Baeck, Chang Won; Kim, Yong Sik; Chun, Hoon-Jai; Lee, Hong Sik; Um, Soon-Ho; Choi, Jai Hyun; Kim, Chang Duck; Ryu, Ho Sang; Hyun, Jin Hai.
In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 46, No. 4, 01.01.2005, p. 297-301.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy
AU - Park, Sang Hoon
AU - Jeen, Yoon Tae
AU - Chun, Hwang Rae
AU - Kim, Dong Il
AU - Baeck, Chang Won
AU - Kim, Yong Sik
AU - Chun, Hoon-Jai
AU - Lee, Hong Sik
AU - Um, Soon-Ho
AU - Choi, Jai Hyun
AU - Kim, Chang Duck
AU - Ryu, Ho Sang
AU - Hyun, Jin Hai
PY - 2005/1/1
Y1 - 2005/1/1
N2 - Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.
AB - Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.
UR - http://www.scopus.com/inward/record.url?scp=33644921817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644921817&partnerID=8YFLogxK
M3 - Article
C2 - 16247274
AN - SCOPUS:33644921817
VL - 46
SP - 297
EP - 301
JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
SN - 1598-9992
IS - 4
ER -